Search Result

Results for "

H -ATPase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Na+/K+ ATPase (2) Antibiotic (3) Apoptosis (15) Autophagy (7) Bacterial (19) DNA/RNA Synthesis (2) Endogenous Metabolite (1) Fungal (1) HIV (1) Influenza Virus (1) Isotope-Labeled Compounds (8) Potassium Channel (3) Proton Pump (54) TGF-beta/Smad (1) TOPK (2) VSV (1)
By Research Areas:	Cancer (29) Cardiovascular Disease (1) Endocrinology (14) Infection (9) Inflammation/Immunology (29) Metabolic Disease (14)

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Targets Recommended: Na+/K+ ATPase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100414

Soraprazan 1 Publications Verification BYK61359	Proton Pump	Metabolic Disease
Soraprazan (BYK61359) is a selective, reversible K-competitive inhibitor of the *H,K-ATPase* (K_i=6.4 nM), with an IC₅₀ of 0.19 μM in gastric glands. Soraprazan binds to the H,K-ATPase with a Kd of 28.27 nM. Soraprazan shows immediate inhibition of acid secretion and is more than 2000-fold selective for H,K-ATPase over Na,K- and Ca-ATPases .

HY-P3711

SPAI-1	Na+/K+ ATPase	Others
SPAI-1 is a specific inhibitor for monovalent cation transporting ATPases. SPAI-1 is a peptide isolated from porcine duodenum, inhibits Na ⁺, K ⁺-ATPase and H ⁺, K ⁺-ATPase in vitro, stimulates Mg ²⁺-ATPase .

HY-U00222

S3337

Proton Pump Inflammation/Immunology

S3337 is an H ⁺, K ⁺-ATPase inhibitor.
HY-U00042

SKF96067

Proton Pump Inflammation/Immunology

SKF96067 is a reversible inhibitor of the gastric H ⁺/K ⁺-ATPase.
HY-15384

Picoprazole

Proton Pump Metabolic Disease

Picoprazole is a specific inhibitor of H ⁺/K ⁺-ATPase with IC₅₀ of 3.1±0.4 μM.

S3337	Proton Pump	Inflammation/Immunology
S3337 is an H ⁺, K ⁺-ATPase inhibitor.

SKF96067	Proton Pump	Inflammation/Immunology
SKF96067 is a reversible inhibitor of the gastric H ⁺/K ⁺-ATPase.

Picoprazole	Proton Pump	Metabolic Disease
Picoprazole is a specific inhibitor of H ⁺/K ⁺-ATPase with IC₅₀ of 3.1±0.4 μM.

HY-B1446

Esomeprazole magnesium (S)-Omeprazole magnesium; (-)-Omeprazole magnesium
Esomeprazole magnesium ((S)-Omeprazole magnesium) is a potent and orally active H ⁺, K ⁺-ATPase inhibitor. Esomeprazole magnesium has the potential for upper intestinal disorders and gastroesophageal reflux disease research . Esomeprazole magnesium acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H ⁺-ATPases .

HY-17623

Tegoprazan 2 Publications Verification CJ-12420; RQ-00000004
Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a potent, oral active and highly selective inhibitor of gastric H ⁺/K ⁺-ATPase that could control gastric acid secretion and motility, with IC₅₀ values ranging from 0.29-0.52 μM for porcine, canine, and human H ⁺/K ⁺-ATPases in vitro .

HY-17623C

(R)-Tegoprazan (R)-CJ-12420; (R)-RQ-00000004	Proton Pump	Metabolic Disease
(R)-Tegoprazan (example 3), a benzimidazole derivative, is a potent kidney H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 98 nM of canine kidney Na ⁺/K ⁺-ATPase. (R)-Tegoprazan has the potential for gastrointestinal diseases research .

HY-W008614

Lansoprazole sulfone 1 Publications Verification AG-1813	Proton Pump	Metabolic Disease
Lansoprazole sulfone (AG-1813) is an orally active and selective inhibitor of H ⁺, K ⁺-ATPase. Lansoprazole sulfone can significantly stimulates gastric acid secretion by inhibiting H ⁺, K ⁺-ATPase. Lansoprazole sulfone has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease .

HY-17022

Esomeprazole magnesium trihydrate (S)-Omeprazole magnesium trihydrate; (-)-Omeprazole magnesium trihydrate	Proton Pump	Endocrinology Cancer
Esomeprazole magnesium trihydrate ((S)-Omeprazole magnesium trihydrate) is a potent and orally active H ⁺, K ⁺-ATPase inhibitor. Esomeprazole magnesium trihydrate has the potential for upper intestinal disorders and gastroesophageal reflux disease research . Esomeprazole magnesium trihydrate acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H ⁺-ATPases .

HY-N1724

Concanamycin A 5+ Cited Publications Antibiotic X 4357B; Folimycin; X 4357B
Concanamycin A (Folimycin; Antibiotic X 4357B) is a macrolide antibiotic, a vacuolar type H ⁺-ATPase (V-ATPase) inhibitor. Concanamycin A is also an inhibitor of lysosomal acidification, can be used to T cell-mediated inflammation research ^- .

HY-125707

Concanamycin B

MCH 210
Proton Pump Antibiotic Infection

Concanamycin B is a macrolide antibiotic, which can inhibit the cavitation type H+-ATPases, and the IC₅₀ value is 5 nM .

Concanamycin B MCH 210	Proton Pump Antibiotic	Infection
Concanamycin B is a macrolide antibiotic, which can inhibit the cavitation type *H+-ATPases, and the IC₅₀* value is 5 nM .

HY-17023

Esomeprazole sodium (S)-Omeprazole sodium; (-)-Omeprazole sodium	Proton Pump Bacterial	Endocrinology Cancer
Esomeprazole sodium ((S)-Omeprazole sodium) is a potent and orally active proton pump inhibitor. Esomeprazole reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H ⁺-ATPases . Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-100560S

Abscisic acid-d6 (S)-(+)-Abscisic acid-d₆; ABA-d₆	Proton Pump	Metabolic Disease
Abscisic acid-d₆ is deuterium labeled Abscisic acid. Abscisic acid inhibits proton pump (H+-ATPase)[1].

HY-13100

PF 03716556	Proton Pump	Metabolic Disease
PF 03716556 is a potent, selective, competitive and reversible acid pump (H ⁺,K ⁺-ATPase) antagonist with pIC₅₀s of 6.026, 6.038 and 6.009 for porcine, canine, and human recombinant gastric H ⁺,K ⁺-ATPase, respectively. PF 03716556 is inactive against other receptors, ion channels, and enzymes. PF 03716556 has the potential for gastroesophageal reflux disease research .

HY-17623D

Tegoprazan Benzoate CJ-12420 Benzoate; RQ-00000004 Benzoate	Proton Pump	Metabolic Disease
Tegoprazan Benzoate is the benzoate form of Tegoprazan (HY-17623). Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a potent, oral active and highly selective inhibitor of gastric H ⁺/K ⁺-ATPase that could control gastric acid secretion and motility, with IC₅₀ values ranging from 0.29-0.52 μM for porcine, canine, and human H ⁺/K ⁺-ATPases in vitro .

HY-N10239

Aquastatin A	Others	Metabolic Disease
Aquastatin A is an inhibitor of mammalian adenosine triphosphatases. Aquastatin A is isolated from a fungus identified as Fusarium aquaeductuum. Aquastatin A inhibits Na+/K(+)-ATPase with an IC₅₀ value of 7.1 μM, and H+/K(+)-ATPase with an apparent IC₅₀ value of 6.2 μM .

HY-17421A

Tenatoprazole sodium TU-199 sodium	Proton Pump	Cardiovascular Disease
Tenatoprazole sodium (TU-199 sodium) is a proton pump inhibitor; inhibits hog gastric H ⁺/K ⁺-ATPase with an IC₅₀ of 6.2 μM.

HY-N2033

Chebulinic acid 1 Publications Verification	DNA/RNA Synthesis TGF-beta/Smad Proton Pump	Infection
Chebulinic acid is a potent natural inhibitor of M. tuberculosis DNA gyrase, also can inhibit SMAD-3 phosphorylation, inhibit H+ K+-ATPase activity.

HY-17023R

Esomeprazole sodium (Standard) (S)-Omeprazole sodium (Standard); (-)-Omeprazole sodium (Standard)	Proton Pump Bacterial	Endocrinology Cancer
Esomeprazole (sodium) (Standard) is the analytical standard of Esomeprazole (sodium). This product is intended for research and analytical applications. Esomeprazole sodium ((S)-Omeprazole sodium) is a potent and orally active proton pump inhibitor. Esomeprazole reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H ⁺-ATPases . Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-100412

Linaprazan AZD0865	Proton Pump	Cancer
Linaprazan (AZD0865) can inhibit H+,K+ -ATPase in the stomach through K+ competitive binding. (IC 50: 1.0 ± 0.2 μM), it has a strong inhibitory effect on acid.

HY-W008614S

Lansoprazole sulfone-d4 AG-1813-d₄	Isotope-Labeled Compounds Proton Pump	Others
Lansoprazole sulfone-d₄ (AG-1813-d₄) is the deuterium labeled Lansoprazole sulfone. Lansoprazole sulfone-d₄ is an orally active and selective inhibitor of H ⁺, K ⁺-ATPase. Lansoprazole sulfone-d₄ can significantly stimulates gastric acid secretion by inhibiting H ⁺, K ⁺-ATPase. Lansoprazole sulfone-d₄ has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease .

HY-130173

Bafilomycin C1	Bacterial Fungal Na+/K+ ATPase Apoptosis Antibiotic	Infection Cancer
Bafilomycin C1 is a macrolide antibiotic isolated from Streptomyces sp. Bafilomycin C1 is a potent, specific and reversible inhibitor of vacuolar-type H ⁺-ATPases (V-ATPases). Bafilomycin C1 inhibits growth of gram-positive bacteria and fungi . Bafilomycin C1 induces cell apoptosis and can be used for the study of hepatocellular carcinoma (HCC) .

HY-W003467

Rabeprazole Sulfide	Proton Pump Bacterial	Infection Inflammation/Immunology
Rabeprazole Sulfide is an active metabolite of Rabeprazole. Rabeprazole is a proton pump inhibitor that suppresses gastric acid secretion through an interaction with (H ⁺/K ⁺)-ATPase in gastric parietal cells. Rabeprazole markedly inhibits the motility of *H. pylori*. Rabeprazole has the potential for various peptic diseases treatment .

HY-103261

SCH28080	Proton Pump	Endocrinology
SCH28080 is a reversible, K ⁺-competitive inhibitor of the gastric H,K-ATPase, with a K_i of 0.12 μM. SCH28080 is an effective inhibitor of acid secretion in vivo and with anti-gastric ulcer activity .

HY-149887

H3B-968	DNA/RNA Synthesis	Cancer
H3B-968 is a potent inhibitor of Werner syndrome protein (WRN) (IC₅₀=~10 nM)，which acts function as helicase，ATPase，and exonuclease. WRN exhibits synthetic lethal activity in cancer research. However，H3B-968 inhibits WRN helicase activity，competitively with ATP .

HY-100558

Bafilomycin A1 Maximum Cited Publications 369 Publications Verification BafA1	Proton Pump Autophagy Antibiotic Bacterial Apoptosis	Infection Cancer
Bafilomycin A1 (BafA1) is a specific and reversible inhibitor of vacuolar H ⁺-ATPase (V-ATPase) with IC₅₀ values of 4-400 nmol/mg. Bafilomycin A1, a macrolide antibiotic, is also used as an autophagy inhibitor at the late stage. Bafilomycin A1 blocks autophagosome-lysosome fusion and inhibits acidification and protein degradation in lysosomes of cultured cells. Bafilomycin A1 induces apoptosis .

HY-U00193

Ro18-5362	Others	Metabolic Disease
Ro18-5362 is the less active proagent of Ro 18-5364. Even at concentrations as high as 0.1 mM Ro 18-5362 fails to affect significantly (H ⁺+K ⁺)-ATPase activity and associated proton translocation.

HY-N7031

(±)-Vasicine (±)-Peganine	Proton Pump	Inflammation/Immunology
(±)-Vasicine is the racemate of Vasicine. Vasicine (Peganine) significantly inhibits H ⁺-K ⁺-ATPase activity in vitro with an IC₅₀ of 73.47 μg/mL. Anti-ulcer activity. Vasicine shows significant anti-secretory, antioxidant and cytoprotective effect .

HY-A0213

Tiludronate Tiludronic acid
Tiludronate (Tiludronic Acid), an orally active bisphosphonate, can act an osteoregulator. Tiludronate is used for the research of the metabolic bone disorders. Tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. Antiresorptive and anti-inflammatory properties .

HY-17021B

Esomeprazole potassium salt (S)-Omeprazole potassium salt; (-)-Omeprazole potassium salt	Proton Pump Bacterial	Inflammation/Immunology Endocrinology Cancer
Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole potassium salt has the potential for symptomatic gastroesophageal reflux disease research .

HY-A0213A

Tiludronate disodium Tiludronic acid disodium	Proton Pump	Inflammation/Immunology
Tiludronate (Tiludronic Acid) disodium, an orally active bisphosphonate, can act an osteoregulator. Tiludronate is used for the research of the metabolic bone disorders. Tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. Antiresorptive and anti-inflammatory properties .

HY-109079A

Abeprazan hydrochloride DWP14012 hydrochloride; Fexuprazan hydrochloride	Proton Pump	Metabolic Disease
Abeprazan hydrochloride (DWP14012 hydrochloride) is a potassium-competitive acid blocker. Abeprazan hydrochloride inhibits H ⁺, K ⁺- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan hydrochloride is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases .

HY-109079

Abeprazan DWP14012; Fexuprazan	Proton Pump	Metabolic Disease
Abeprazan (DWP14012) is a potassium-competitive acid blocker. Abeprazan inhibits H ⁺, K ⁺- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases .

HY-17021

Esomeprazole (S)-Omeprazole; (-)-Omeprazole	Proton Pump Bacterial	Inflammation/Immunology Endocrinology Cancer
Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-N2532

Diphyllin	VSV HIV Proton Pump Influenza Virus	Infection Inflammation/Immunology Cancer
Diphyllin is an arylnaphthalene lignan isolated from Justicia procumbens and is a potent HIV-1 inhibitor with an IC50 of 0.38 μM. Diphyllin is active against vesicular stomatitis virus (VSV) and influenza virus . Diphyllin is a vacuolar type H ⁺-ATPase (V-ATPase) inhibitor with an IC₅₀ value of 17 nM and inhibits lysosomal acidification in human osteoclasts . Diphyllin inhibits NO production with an IC₅₀ of 50 μM and has anticancer and anti-inflammatory activities .

HY-A0213B

Tiludronate disodium hemihydrate Tiludronic acid disodium hemihydrate	Proton Pump	Metabolic Disease
Tiludronate (Tiludronic Acid) disodium hemihydrate, an orally active bisphosphonate, can act an osteoregulator. Tiludronate disodium hemihydrate is used for the research of the metabolic bone disorders. Tiludronate disodium hemihydrate is a potent inhibitor of the osteoclast vacuolar H ⁺-ATPase. Antiresorptive and anti-inflammatory properties .

HY-17021C

Esomeprazole hemistrontium (S)-Omeprazole hemistrontium; (-)-Omeprazole hemistrontium	Proton Pump Bacterial	Inflammation/Immunology Endocrinology Cancer
Esomeprazole ((S)-Omeprazole) hemistrontium is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole hemistrontium has the potential for symptomatic gastroesophageal reflux disease research .

HY-W003467R

Rabeprazole Sulfide (Standard)	Proton Pump Bacterial	Infection Inflammation/Immunology
Rabeprazole Sulfide (Standard) is the analytical standard of Rabeprazole Sulfide. This product is intended for research and analytical applications. Rabeprazole Sulfide is an active metabolite of Rabeprazole. Rabeprazole is a proton pump inhibitor that suppresses gastric acid secretion through an interaction with (H ⁺/K ⁺)-ATPase in gastric parietal cells. Rabeprazole markedly inhibits the motility of *H. pylori*. Rabeprazole has the potential for various peptic diseases treatment .

HY-17021A

Esomeprazole magnesium salt (S)-Omeprazole magnesium salt; (-)-Omeprazole magnesium salt	Proton Pump Bacterial	Inflammation/Immunology Endocrinology Cancer
Esomeprazole magnesium salt ((S)-Omeprazole magnesium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole magnesium salt has the potential for symptomatic gastroesophageal reflux disease research .

HY-100413

CS-526
CS-526 is a potent, selective, reversible and orally active acid pump antagonist. CS-526 inhibits H ⁺,K ⁺-ATPase activity. CS-526 inhibits gastric acid secretion and prevents esophageal lesions. CS-526 has the potential for the research of gastroesophageal reflux disease .

HY-17023S

Esomeprazole-d6 sodium (S)-Omeprazole-d6 sodium; (-)-Omeprazole-d6 sodium	Isotope-Labeled Compounds Proton Pump	Others
Esomeprazole-d₆ sodium is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-17021S

Esomeprazole-d3 sodium	Isotope-Labeled Compounds Proton Pump	Inflammation/Immunology Endocrinology Cancer
Esomeprazole-d₃ (sodium) is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].

HY-17021S1

Esomeprazole-d3	Isotope-Labeled Compounds Proton Pump	Inflammation/Immunology Endocrinology Cancer
Esomeprazole-d₃ is deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].

HY-122815

Fusicoccin Fusicoccin A	Apoptosis	Cancer
Fusicoccin (Fusicoccin A), a fungal pytotoxin, is a stabilizer of specific 14-3-3 protein-protein interactions. Fusicoccin sabilizes H ⁺-ATPase/14-3-3 cmplex in pants, maintaining the enzyme in activated state. Fusicoccin also stabilizes 14-3-3 protein interactions with binding partners containing a C-terminal 14-3-3 recognition motif (a mode 3 motif), such as ERα, GPIbα, TASK3, CTFR, and p53. Fusicoccin induces apoptosis in cancer cells and has anticancer activity .

HY-B0656

Rabeprazole 2 Publications Verification LY307640	Proton Pump Apoptosis Bacterial	Inflammation/Immunology Cancer
Rabeprazole (LY307640) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H ⁺/K ⁺-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-B0656A

Rabeprazole sodium 2 Publications Verification LY307640 sodium	Proton Pump Apoptosis Bacterial	Inflammation/Immunology Cancer
Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H ⁺/K ⁺-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-A0213AS

Tiludronate-d5 sodium Tiludronic acid-d₅ (sodium)	Proton Pump	Inflammation/Immunology
Tiludronate-d₅ (sodium)mis the deuterium labeled Tiludronate disodium. Tiludronate (Tiludronic Acid) disodium, an orally active bisphosphonate, can act an osteoregulator. Tiludronate is used for the research of the metabolic bone disorders. Tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. Antiresorptive and anti-inflammatory properties[1][2][3][4].

HY-150555

P-CAB agent 1	Potassium Channel	Others
P-CAB agent 1 (compound B19) is a highly potent potassium-competitive acid blocker agent with an IC₅₀ value of 60.50 nM for H ⁺/K ⁺-ATPase. P-CAB agent 1 has acceptable oral absorption in rats. P-CAB agent 1 can be used for researching acid-related disorders (ARDs) .

HY-B2145

Ilaprazole sodium IY-81149 sodium
Ilaprazole (IY-81149) sodium is an orally active proton pump inhibitor. Ilaprazole sodium irreversibly inhibits H ⁺/K ⁺-ATPase in a dose-dependent manner with an IC₅₀ of 6 μM in rabbit parietal cell preparation. Ilaprazole sodium is used for the research of gastric ulcers. Ilaprazole sodium is also a potent TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2033

Chebulinic acid 1 Publications Verification	Infection Structural Classification Classification of Application Fields Combretaceae Source classification Phenols Polyphenols Terminalia chebula Retz. Plants Disease Research Fields	DNA/RNA Synthesis TGF-beta/Smad Proton Pump
Chebulinic acid is a potent natural inhibitor of M. tuberculosis DNA gyrase, also can inhibit SMAD-3 phosphorylation, inhibit H+ K+-ATPase activity.

HY-130173

Bafilomycin C1	Infection Structural Classification Microorganisms Macrolide Antibiotics Antibiotics Source classification Antibacterial Disease Research Anticancer Disease Research Fields Cancer	Bacterial Fungal Na+/K+ ATPase Apoptosis Antibiotic
Bafilomycin C1 is a macrolide antibiotic isolated from Streptomyces sp. Bafilomycin C1 is a potent, specific and reversible inhibitor of vacuolar-type H ⁺-ATPases (V-ATPases). Bafilomycin C1 inhibits growth of gram-positive bacteria and fungi . Bafilomycin C1 induces cell apoptosis and can be used for the study of hepatocellular carcinoma (HCC) .

HY-100558

Bafilomycin A1 365+ Cited Publications BafA1	Infection Structural Classification Microorganisms Macrolide Antibiotics Classification of Application Fields Antibiotics Source classification Disease Research Anticancer Disease Research Fields	Proton Pump Autophagy Antibiotic Bacterial Apoptosis
Bafilomycin A1 (BafA1) is a specific and reversible inhibitor of vacuolar H ⁺-ATPase (V-ATPase) with IC₅₀ values of 4-400 nmol/mg. Bafilomycin A1, a macrolide antibiotic, is also used as an autophagy inhibitor at the late stage. Bafilomycin A1 blocks autophagosome-lysosome fusion and inhibits acidification and protein degradation in lysosomes of cultured cells. Bafilomycin A1 induces apoptosis .

HY-125707

Concanamycin B MCH 210	Structural Classification Natural Products Microorganisms Source classification	Proton Pump Antibiotic
Concanamycin B is a macrolide antibiotic, which can inhibit the cavitation type *H+-ATPases, and the IC₅₀* value is 5 nM .

HY-N10239

Aquastatin A	Monophenols Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Phenols Metabolic Disease Disease Research Fields	Others
Aquastatin A is an inhibitor of mammalian adenosine triphosphatases. Aquastatin A is isolated from a fungus identified as Fusarium aquaeductuum. Aquastatin A inhibits Na+/K(+)-ATPase with an IC₅₀ value of 7.1 μM, and H+/K(+)-ATPase with an apparent IC₅₀ value of 6.2 μM .

HY-N7031

(±)-Vasicine (±)-Peganine	Alkaloids Classification of Application Fields Zygophyllaceae Source classification Peganum harmala Linn. Plants Disease Research Fields Inflammation/Immunology	Proton Pump
(±)-Vasicine is the racemate of Vasicine. Vasicine (Peganine) significantly inhibits H ⁺-K ⁺-ATPase activity in vitro with an IC₅₀ of 73.47 μg/mL. Anti-ulcer activity. Vasicine shows significant anti-secretory, antioxidant and cytoprotective effect .

HY-N2532

Diphyllin	Structural Classification Classification of Application Fields Source classification Lignans Dysosma versipellis (Hance) M. Cheng ex Ying Plants Infection Monophenols Phenols Phenylpropanoids Berberidaceae Inflammation/Immunology Disease Research Fields	VSV HIV Proton Pump Influenza Virus
Diphyllin is an arylnaphthalene lignan isolated from Justicia procumbens and is a potent HIV-1 inhibitor with an IC50 of 0.38 μM. Diphyllin is active against vesicular stomatitis virus (VSV) and influenza virus . Diphyllin is a vacuolar type H ⁺-ATPase (V-ATPase) inhibitor with an IC₅₀ value of 17 nM and inhibits lysosomal acidification in human osteoclasts . Diphyllin inhibits NO production with an IC₅₀ of 50 μM and has anticancer and anti-inflammatory activities .

HY-122815

Fusicoccin Fusicoccin A	Microorganisms Classification of Application Fields Terpenoids Source classification Diterpenoids Disease Research Fields Cancer	Apoptosis
Fusicoccin (Fusicoccin A), a fungal pytotoxin, is a stabilizer of specific 14-3-3 protein-protein interactions. Fusicoccin sabilizes H ⁺-ATPase/14-3-3 cmplex in pants, maintaining the enzyme in activated state. Fusicoccin also stabilizes 14-3-3 protein interactions with binding partners containing a C-terminal 14-3-3 recognition motif (a mode 3 motif), such as ERα, GPIbα, TASK3, CTFR, and p53. Fusicoccin induces apoptosis in cancer cells and has anticancer activity .

HY-100560

Abscisic acid (S)-(+)-Abscisic acid; ABA	Structural Classification Classification of Application Fields Source classification Metabolic Disease Plants Endogenous metabolite Agricultural Research other families Microorganisms Animals Terpenoids Sesquiterpenes Abscisic acid Phytohormone Disease Research Fields	Endogenous Metabolite Proton Pump
Abscisic acid ((S)-(+)-Abscisic acid), an orally active phytohormone in fruits and vegetables, is an endogenously produced mammalian hormone. Abscisic acid is a growth inhibitor and can regulate many aspects of plant growth and development. Abscisic acid inhibits proton pump (H ⁺-ATPase) and leads to the plasma membrane depolarization in a Ca ²⁺-dependent manner. Abscisic acid, a LANCL2 natural ligand, is a potent insulin-sensitizing compound and has the potential for pre-diabetes, type 2 diabetes and metabolic syndrome .

Species:	Human (5)
Tag:	His (5) SUMO (3)
Source:	E. coli (5)

Cat. No.	Compare	Product Name	Species	Source

HY-P72099

	ATP6AP2 Protein, Human (His) APT6M8 9; APT6M8-9; ATP6AP2; ATP6IP2; ATP6M8-9; ATPase H+; -transporting lysosomal accessory protein 2; ATPase H+; -transporting lysosomal-interacting protein 2; ATPase H+ transporting lysosomal accessory protein 2; ATPase; H+ transporting; lysosomal vacuolar proton pump; membrane sector associated protein M8 9;	Human	E. coli
	The multifunctional ATP6AP2 protein serves as a cellular receptor for renin and prorenin, contributing to lysosomal V-ATPase assembly and endolysosomal acidification. It participates in renin-dependent reactions, activates ERK1/2, and may enhance the catalytic efficiency of renin in the renin-angiotensin system. ATP6AP2 Protein, Human (His) is the recombinant human-derived ATP6AP2 protein, expressed by E. coli , with N-6*His labeled tag. The total length of ATP6AP2 Protein, Human (His) is 334 a.a., with molecular weight of ~40 kDa.

HY-P72098

	ATP5D Protein, Human (His) ATP synthase subunit delta; mitochondrial ; ATP synthase subunit delta; mitochondrial; ATP synthase; H+ transporting; mitochondrial F1 complex; delta subunit; ATP5D; ATPD_HUMAN; F ATPase delta subunit ; F-ATPase delta subunit; Mitochondrial ATP synthase complex delta subunit precusor ; Mitochondrial ATP synthase delta subunit	Human	E. coli
	ATP5D Protein, a vital component of mitochondrial membrane ATP synthase (Complex V), facilitates ATP generation from ADP using the proton gradient established by respiratory chain electron transport complexes. As part of the F(1) domain and central stalk, ATP5D contributes to ATP hydrolysis through a rotary mechanism. The ATP synthase complex, involving ATP5D, is pivotal for cellular energy production via ATP synthesis. ATP5D Protein, Human (His) is the recombinant human-derived ATP5D protein, expressed by E. coli , with N-10*His labeled tag. The total length of ATP5D Protein, Human (His) is 146 a.a., with molecular weight of ~20 kDa.

HY-P72100

	ATP6AP2 Protein, Human (His-SUMO) APT6M8 9; APT6M8-9; ATP6AP2; ATP6IP2; ATP6M8-9; ATPase H+; -transporting lysosomal accessory protein 2	Human	E. coli
	The multifunctional ATP6AP2 protein serves as a cellular receptor for renin and prorenin, contributing to lysosomal V-ATPase assembly and endolysosomal acidification. It participates in renin-dependent reactions, activates ERK1/2, and may enhance the catalytic efficiency of renin in the renin-angiotensin system. ATP6AP2 Protein, Human (His-SUMO) is the recombinant human-derived ATP6AP2 protein, expressed by E. coli , with N-6*His, N-SUMO labeled tag. The total length of ATP6AP2 Protein, Human (His-SUMO) is 334 a.a., with molecular weight of ~53.5 kDa.

HY-P72097

	ATP5D Protein, Human (His-SUMO) ATP synthase subunit delta; mitochondrial ; ATP synthase subunit delta; mitochondrial; ATP synthase; H+ transporting; mitochondrial F1 complex; delta subunit; ATP5D; ATPD_HUMAN; F ATPase delta subunit ; F-ATPase delta subunit; Mitochondrial ATP synthase complex delta subunit precusor ; Mitochondrial ATP synthase delta subunit	Human	E. coli
	ATP5D Protein, a vital component of mitochondrial membrane ATP synthase (Complex V), facilitates ATP generation from ADP using the proton gradient established by respiratory chain electron transport complexes. As part of the F(1) domain and central stalk, ATP5D contributes to ATP hydrolysis through a rotary mechanism. The ATP synthase complex, involving ATP5D, is pivotal for cellular energy production via ATP synthesis. ATP5D Protein, Human (His-SUMO) is the recombinant human-derived ATP5D protein, expressed by E. coli , with N-6*His, N-SUMO labeled tag. The total length of ATP5D Protein, Human (His-SUMO) is 146 a.a., with molecular weight of ~31 kDa.

HY-P72096

	ATP5F1A Protein, Human (His-SUMO) ATP synthase alpha chain; ATP synthase alpha chain; mitochondrial; ATP synthase subunit alpha; ATP synthase subunit alpha mitochondrial; ATP synthase; H+ transporting; mitochondrial F1 complex; alpha subunit 1; cardiac muscle; ATP synthase; H+ transporting; mitochondrial F1 complex; alpha subunit; 1; ATP synthase; H+ transporting; mitochondrial F1 complex; alpha subunit; isoform 1; cardiac muscle; ATP synthase; H+ transporting; mitochondrial F1 complex; alpha subunit; isoform 2; non-cardiac muscle-like 2; ATP sythase F1 ATPase; alpha subunit; ATP5A; Atp5a1; ATP5AL2; ATPA_HUMAN; ATPM; Epididymis secretory sperm binding protein Li 123m; hATP1; HEL-S-123m; MC5DN4; mitochondrial; Mitochondrial ATP synthetase; Mitochondrial ATP synthetase oligomycin resistant; Modifier of Min 2; Modifier of Min 2 mouse homolog; Modifier of Min 2; mouse; homolog of; MOM2; OMR; ORM; OTTHUMP00000163475	Human	E. coli
	ATP5F1A is an important component of mitochondrial ATP synthase (complex V) that coordinates ATP production from ADP by utilizing the transmembrane proton gradient. As part of the F-type ATPase, the α and β subunits of ATP5F1A form the catalytic core to achieve ATP hydrolysis. ATP5F1A Protein, Human (His-SUMO) is the recombinant human-derived ATP5F1A protein, expressed by E. coli , with N-6*His, N-SUMO labeled tag. The total length of ATP5F1A Protein, Human (His-SUMO) is 510 a.a., with molecular weight of ~71.2 kDa.

Cat. No.	Product Name	Chemical Structure

HY-100560S

Abscisic acid-d6

Abscisic acid-d₆ is deuterium labeled Abscisic acid. Abscisic acid inhibits proton pump (H+-ATPase)[1].

HY-W008614S

Lansoprazole sulfone-d4

Lansoprazole sulfone-d₄ (AG-1813-d₄) is the deuterium labeled Lansoprazole sulfone. Lansoprazole sulfone-d₄ is an orally active and selective inhibitor of H ⁺, K ⁺-ATPase. Lansoprazole sulfone-d₄ can significantly stimulates gastric acid secretion by inhibiting H ⁺, K ⁺-ATPase. Lansoprazole sulfone-d₄ has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease .

HY-17023S

Esomeprazole-d6 sodium
Esomeprazole-d₆ sodium is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-17021S

Esomeprazole-d3 sodium
Esomeprazole-d₃ (sodium) is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].

HY-17021S1

Esomeprazole-d3
Esomeprazole-d₃ is deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].

HY-A0213AS

Tiludronate-d5 sodium
Tiludronate-d₅ (sodium)mis the deuterium labeled Tiludronate disodium. Tiludronate (Tiludronic Acid) disodium, an orally active bisphosphonate, can act an osteoregulator. Tiludronate is used for the research of the metabolic bone disorders. Tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. Antiresorptive and anti-inflammatory properties[1][2][3][4].

HY-B0656S

Rabeprazole-d4
Rabeprazole-d₄ is a deuterium labeled Rabeprazole. Rabeprazole is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux[1][2][3].

HY-B0656AS

Rabeprazole-d4 sodium

Rabeprazole-d₄ (sodium) is the deuterium labeled Rabeprazole sodium. Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux[1][2][3].

HY-B0656AS1

Rabeprazole-d3 sodium

Rabeprazole-d₃ (sodium)mis the deuterium labeled Rabeprazole sodium. Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux[1][2][3].

HY-17507S

Pantoprazole-d6

Pantoprazole-d₆ is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI)[1]. Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142)[3][4].

HY-17507S1

Pantoprazole-d3

Pantoprazole-d₃ is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI)[1]. Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142)[3][4].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks